Chemical Component Summary

Name(6M)-6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
Identifiers6-[2,3-bis(chloranyl)phenyl]-1,2,4-triazine-3,5-diamine
FormulaC9 H7 Cl2 N5
Molecular Weight256.091
TypeNON-POLYMER
Isomeric SMILESc1cc(c(c(c1)Cl)Cl)c2c(nc(nn2)N)N
InChIInChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
InChIKeyPYZRQGJRPPTADH-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count23
Chiral Atom Count0
Bond Count24
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB00555 
NameLamotrigine
Groups
  • investigational
  • approved
DescriptionLamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries.[A191350] Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850]
Synonyms
  • Lamotrigina
  • 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
  • Lamotriginum
  • Lamotrigine
Brand Names
  • Ratio-lamotrigine
  • Lamictal XR
  • Lamictal
  • Lamotrigine-100
  • Lamictal - Tab 200mg
IndicationLamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.[L9404] It is also indicated for the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).[L9404] In addition to the above, lamotrigine is also indicated for the maintenance treatment of bipolar I disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been treated for acute mood symptoms with standard therapy.[L9404] Limitations of use It is important to note that lamotirigine should not be used in the treatment of acute mood episodes, as efficacy has not been established in this context.[L9404]
Categories
  • Agents causing hyperkalemia
  • Agents producing tachycardia
  • Anti-epileptic Agent
  • Antiarrhythmic agents
  • Anticholinergic Agents
ATC-CodeN03AX09
CAS number84057-84-1

Drug Targets

NameTarget SequencePharmacological ActionActions
Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E)MARFGEAVVARPGSGDGDSDQSRNRQGTPVPASGQAAAYKQTKAQRARTM...unknowninhibitor
Voltage-gated sodium channel alpha subunitMEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPK...unknowninhibitor
Adenosine receptor A1MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVS...unknowninhibitor
Adenosine receptor A2aMPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAA...unknowninhibitor
Alpha-1A adrenergic receptorMVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL741
PubChem 3878
ChEMBL CHEMBL741
ChEBI CHEBI:6367